Tab-cel Returns to FDA With a Rebuilt Evidence Package

Company Atara Biotherapeutics / Pierre Fabre Event Type Regulatory / BLA Resubmission Modality Allogeneic T-Cell Immunotherapy Asset Tabelecleucel (tab-cel, Ebvallo) Target EBV Antigens (HLA-Restricted) Disease Area EBV-Positive Post-Transplant Lymphoproliferative Disease Summary Pierre Fabre, supported by Atara Biotherapeutics, resubmitted the U.S. biologics license application for tabelecleucel…